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Abstract Bone morphogenetic pro-
teins (BMPs) were discovered by
Urist and colleagues in 1965 and
later defined as multifunctional
cytokines involved in osteoinduc-
tion. BMPs are members of the
transforming growth factor-β super-
family, with the exception of the
BMP-1. Presently, at least 20 BMPs
have been identified and studied,
but only BMP 2, 4 and 7 have been
able in vitro to stimulate the entire
process of stem cell differentiation
into osteoblastic mature cells. In
preclinical and clinical studies,
BMPs have demonstrated potential
in osteoinduction and have been
approved for clinical use in treating
open fractures of the long bones
and nonunions and in vertebral
arthrodesis. Additional clinical uses
of these molecules are under inves-
tigation and the possibility of using
gene therapy in selected patholo-
gies seems the most appealing.
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Spinal fusion
Subsequent to animal studies that attribuited high fusion
rates to the use of osteoinductive proteins in noninstru-
mented posterolateral fusions, Johnsson et al. [4] random-
ized 20 patients to fusion with either BMP-7 (OP-1
Implant, Stryker) or autograft bone from the iliac crest. At
surgery, 0.8-mm metallic markers were positioned in L5
and in the sacrum, enabling radiostereometric follow-up
analysis for 1 year. The patients kept the trunk straight for
5 months after surgery with the aid of a soft lumbar brace.
The three-dimensional vertebral movements were calculat-
ed with an accuracy of 0.5–0.7 mm and 0.5°–2.0°. The
Introduction
Bone morphogenic proteins (BMPs) were discovered by
Urist et al. [1] in 1965. Since then, more than 20 BMPs
have been identified and, with the exception of BMP-1, all
are members of the transforming growth factor (TGF)-β
superfamily. BMPs are now defined as multifunctional
cytokines involved in osteoinduction. They are probably
the most important growth factors in bone formation and
healing [2]. They share action with a number of other mol-
ecules, all members of the TGF-β superfamily, but their
effects are superior [3] and more specific, as extensively
shown by several clinical trials [4, 5].
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study failed to show a significant difference between the
OP-1 Implant and fusion with autograft bone. A significant
relation between reduced vertebral movements and better
bone formation was demonstrated. No adverse effects of
the OP-1 Implant occurred, while persistent minor pain at
the iliac crest was noticed in one patient in the autograft
group. In conclusion there was no significant difference
between the two fusion versions. The same outcome of
comparable results with OP-1 added to autograft bone was
reported by Vaccaro et al. [5] who, in a pilot clinical trial,
observed a successful fusion in 55% of patients (which was
not significantly different from the 45% fusion rate
obtained in a historical control group of autograft alone).
Boden et al. [6] reported the results of lumbar interbody
arthrodesis for 14 patients with a single-level lumbar degen-
erative disc disease. Patients were treated with tapered
cylindrical threaded fusion cage filled with rhBMP-2/colla-
gen sponge or autogenous iliac crest bone. They were eval-
uated with radiography, computed tomography (CT), and
the Short Form-36 (SF-36) and Oswestry outcome question-
naires. All 11 patients who received rhBMP-2 were judged
by three independent radiologists to have solid fusions at the
6-month postoperative visit, whereas only 2 of the 3 control
patients were deemed to be fused. The Owestry Disability
Questionnaire scores of the rhBMP-2 group improved soon-
er (after 3 months) than those of the autograft group, but
both groups demonstrated similar improvements at 6
months. SF-36 scores continued to improve up to 24
months. In conclusion, arthrodesis occurred more reliably in
patients treated with rhBMP-2-filled fusion cages than in
controls with autogenous bone graft, and there were no
adverse events related to the rhBMP-2 treatment. We note,
however, that the sample size of this study was limited.
A larger number of patients were evaluated by Burkus et
al. [7]. In a prospective randomized study, they investigated
42 patients who underwent a single-level anterior lumbar
interbody fusion using cylindrical interbody fusion cages.
Two groups were formed: 22 patients underwent interbody
fusion using two tapered cylindrical fusion cages (LT-
CAGE) and rhBMP-2 on an absorbable collagen sponge,
and 20 patients (control group) underwent the procedure
receiving the devices and autogenous iliac crest bone graft.
Plain radiographs and CT scans were used to evaluate the
pattern of osteoinduction in the interbody space and the pro-
gression of fusion 6, 12, and 24 months after surgery. All the
patients who received rhBMP-2 showed radiographic evi-
dence of osteoinduction in the interbody cages 6 months
after surgery. New bone formation occurred in the disc space
outside the cages by 6 months in 18 of the patients in the
investigational group (82%). By 24 months, all patients in
the investigational group showed new bone formation out-
side the cages. In the autograft control group, 10 patients
(50%) showed evidence of bone formation outside the
cages. Therefore definite evidence of osteoinductive proper-
ties of rhBMP-2 was supported by these data that showed in
a clinical setting accelerated spinal fusion and new bone
apposition under the influence of the morphogenetic protein.
Fracture and nonunions
Friedlaender et al. [8] enrolled 122 patients (124 tibial non-
unions) in a pilot randomized controlled, partially blinded,
multicenter clinical trial and followed them at frequent inter-
vals over 24 months. Each patient was treated by insertion of
an intramedullary rod, accompanied by rhOP-1 in a type I
collagen carrier or by fresh bone autograft. Assessment crite-
ria included the severity of pain at the fracture site, the abil-
ity to walk with full weight-bearing, the need for surgical re-
treatment of the nonunion during the course of this study,
plain radiographic evaluation of healing, and physician satis-
faction with the clinical course. In addition, adverse events
were recorded, and patients were screened for antibodies to
OP-1 and type I collagen at each visit. At 9 months follow-
ing the operative procedures, 81% of the OP-1-treated
nonunions (n=63) and 85% of those receiving autogenous
bone (n=61) were judged by clinical criteria to have been
treated successfully (p=0.524). By radiographic criteria, at
this same time point, 75% of those in the OP-1-treated group
and 84% of the autograft-treated patients had healed frac-
tures (p=0.218). These clinical results continued at similar
levels of success throughout 2 years of observation, and there
was no statistically significant difference in outcome
between the two groups of patients at this point (p=0.939).
More than 20% of patients treated with autografts had chron-
ic donor site pain following the procedure. The conclusion of
the authors were that rhOP-1 (BMP-7), implanted with a type
I collagen carrier, was a safe and effective treatment for tib-
ial nonunions. This molecule provided clinical and radi-
ographic results comparable with those achieved with bone
autograft, without donor site morbidity.
Govender et al. [9] presented the data resulting from a
randomized controlled, single-blind study on 450 patients.
Patients with an open tibial fracture were randomized to
receive either intramedullary nail fixation and routine soft-
tissue management or the same treatment plus an implant
containing either 0.75 mg/ml rhBMP-2 (total dose, 6 mg), or
1.50 mg/ml rhBMP-2 (total dose, 12 mg). The rhBMP-2
implant (rhBMP-2 applied to an absorbable collagen
sponge) was placed over the fracture at the time of definitive
wound closure. At the 12-month follow-up, 421 (94%) of
the patients were controlled. RhBMP-2 group had signifi-
cantly faster fracture-healing (p=0.0022) than did the con-
trol patients and significantly more patients treated with
1.50 mg/ml rhBMP-2 had healing of the fracture at the post-
operative visits from ten weeks through twelve months
(p=0.0008). Patients treated with 1.50 mg/ml rhBMP-2 also
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had significantly fewer infections and faster wound-healing.
The authors concluded that rhBMP-2 implant was safe and,
when 1.50 mg/ml was used, significantly superior to the
standard of care in reducing the frequency of secondary
interventions and the overall invasiveness of the procedures,
accelerating fracture and wound healing, and reducing the
infection rate in patients with an open fracture of the tibia.
Studies on the effects of BMP-2 and BMP-7 on bone
regeneration and healing are summarized in Tables 1 and
2, respectively.
Personal experience
Between 2000 and February 2006, we have treated 82
cases of large bone defects with a combination of homol-
ogous bone, growth factors (platelet-derived growth fac-
tors, PDGF) and fresh bone marrow. From this series of
patients, we retrospectively selected and reviewed those
with cavitary defects and those with orthopaedic prob-
lems, mainly pseudoarthroses, to assess the safety, results
and complications of the procedure. Among the 82 cases,
42 (37 patients) were treated for healing of large defects:
20 males and 17 females. The mean age of the patients
was 19 years (range, 6–54). The lesions were located in 22
cases in the femur, 11 cases in the humerus, 4 cases in the
tibia, 2 cases each in the scapula and calcaneus, and in one
case in the fibula. The original diagnosis for surgery was
an aneurysmal bone cyst in 18 cases, unicameral bone cyst
in 11 cases, fibrous dysplasia in 6 cases, a giant cell tumor
in 4 cases, chondroblastoma in 2 cases and one case of
benign fibrous histiocytoma. In 14 cases (9 patients), the
lesion was treated percutaneously with an infiltration of
autologous fresh bone marrow associated with demineral-
ized bone matrix in only one case. The percutaneous tech-
nique was repeated in 3 patients twice and three times in
one patient who fractured two years after the obtained
healing in a motorcycle accident, sustaining a pertro-
chanteric fracture. The 26 patients operated with standard
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Table 1 Effect of BMP-2 on bone regeneration and healing
Reference Material Results
Sciadini, Johnson [11] Dog radial defect; external fixation and Healing of defects treated with BMP-2, no healing
different doses of BMP-2 of untreated controls. Better mechanical
performance of lower dosage of BMP-2
Bostrom, Camacho [12] Fracture healing of rabbit ulnae Accelerated healing of BMP-2 treated fractures
compared to controls
Burkus et al. [7] Single level lumbar fusion in humans; Accelerated spinal fusion and increased bone
BMP-2 + cages vs. autograft formation inside and outside the cages in
BMP-2-treated group
Govender et al. [9] Healing of open fractures in 450 patients BMP-2 treated group showed faster bone and
wound healing, less need for re-operation, lower
infection rate
Table 2 Effect of BMP-7 (OP-1) on bone regeneration and healing
Reference Material Results
Cook et al. [13] Long bone defect, BMP-7 at different doses Healing of treated defect except for lowest
dosage; mechanical testing similar to intact side,
no healing in control group
den Boer et al. [14] Fracture healing in goats Faster healing with OP-1 independent from
collagenic carrier
Mizumoto et al. [15] Distraction osteogenesis in rats Accelerated osteogenesis in OP-1 group, with
more bone formation also after treatment
Johnsson et al. [4] Lumbar fusion in humans No differences between OP-1 and autograft
Friedlaender et al. [8] Tibial nonunions in humans No differences between OP-1 and autograft
technique of curettage and grafting healed at 121 days on
average (range, 58–279). In some cases the patients lived
far from our institution and did not manage to come to all
the fixed follow-up visits. Therefore we considered the
healing time based on the date of the first follow-up in
which the clinician assessed personally the clinical and
radiological healing. The medium follow-up is 25 months
(range, 6–39). We had two patients with recurrent disease:
one patient with an aneurysmal bone cyst of the proximal
humerus and one patient with a giant cell tumor of the
elbow, 10 and 26 after the original surgeries. The first
patient has already been operated with another curettage,
while the second one has had needle biopsy to confirm the
recurrence. All the remaining 24 patients experienced a
successful result both clinically and radiologically. We did
not experience any surgical site infection or wound com-
plication in this series. No additional recovery time was
needed for the procedure, and the absence of autologous
bone graft harvesting surgical procedure obviously was
associated with the total lack of additional complications
such as pain and blood loss. The surgical time was pro-
longed by one hour on average, which was the time
required for the iliac crest bone marrow harvest and for
operating field changing, for during bone marrow pro-
cessing and bone graft preparation surgery proceeded
without differences.
The 40 patients with orthopaedic pathology were treat-
ed for osteonecrosis of the femoral head in 3 cases and
pseudoarthrosis in 37 cases (Figs. 1 and 2). Femoral head
necrosis was treated with vascularized fibula in one case
and vascularized iliac crest in 2 cases (Fig. 3). In all 3
cases we added homologous morcellized bone mixed with
platelet-rich plasma (PRP) and concentrated fresh bone
marrow. Treatment of pseudoarthrosis was done by the
standard of care (SOC), i.e. appropriate osteosynthesis
and addition of allograft enriched by PRP and concentrat-
ed fresh bone marrow or BMP-7. The 3 cases of femoral
osteonecrosis healed without complications. In the 37
cases of pseudoarthrosis, 7 affected the humerus and 30
affected the lower limb: 16 cases of the femur, 13 cases of
the tibia and one was a subtalar arthrodesis of the talus.
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Fig. 1a-c A 35-year-old woman with an open grade I tibial frac-
ture. a Despite immediate stabilization with an unreamed tibial nail
(titanium), at the 6-month follow-up there was evident nonunion.
b, c Treatment was dinamization of the nail and apposition of allo-
graft and OP-1. Radiographs at one month (b) and 6 months (c)
show complete healing
a b c
Fig. 2a-c Male patient with multiple fractures. a Treatment of the
right tibia with external fixion for an open grade III fracture result-
ed in nonunion. b Intraoperative image after closed reaming and
nailing and exposition of the nonunion site for insertion of OP-1. c
Radiograph at 4 months shows healing of the nonunion
a b c
Fig. 3 An 18-year-old woman with idiopathic osteonecrosis of the
femoral head, treated with vascularized fibula, growth factors and
stem cells. Radiographs at the 2-year follow-up show good conser-
vation of the femoral head
The average age was 30 years (range, 16–65). In 5 cases
we used bone marrow with a percutaneous technique with
a 60% healing rate. The two failures were in the same
patient at the tibia and the femur. In 32 cases we used open
surgery and added bone graft plus PDGF and bone mar-
row in 16 cases, and OP-1 in other 16 cases. The healing
rate was similar for both techniques with a success of
87.5%. Even if there was a higher number of previous sur-
geries in the patients treated with OP-1, still the BMP-7
proved to be effective in these cases with a success rate
similar to less complicated cases.
Conclusions
The satisfactory results obtained by the use of rhBMPs in
clinical settings do not address completely the concerns
regarding safety and cost. BMP-7 have been shown to
elicit a subclinical immune response in one-third of
patients. BMP-2 does not seem to produce immune
responses but its utility in the healing process has been
limited by experimental studies only to the initial phases.
What is still challenging is the migration from experimen-
tal in vitro studies to preclinical and clinical research. The
results of the studies are often contradictory and too many
variables are present that can influence the outcomes of
BMP use: the matrix or carrier used, delivery method, tim-
ing of adding BMPs, and contamination from naturally
delivered growth factors in animal and human trials.
Delivery methods for BMPs and other growth factors are
currently under investigation. Recent research by
Wildemann et al. [10] examined the possibility of coating
osteosynthesis devices with growth factors; by showing
the efficacy of this technique, they introduced a new con-
cept of growth factors delivery in addition to established
fixation devices. This concept could lead to the develop-
ment of specialized fixation devices for nonunion which
already deliver in a controlled way the necessary growth
factor creating true bioactive plating or nailing.
However, there are also other areas that stimulate great
interest for future applications of growth factors to
enhance bone healing: acceleration of fracture healing
(particularly in patients who are at high risk for nonunion)
and treatment of established nonunions by injectable
preparations of BMPs; enhancement of primary spinal
fusion and treatment of established pseudoarthrosis of the
spine; enhancement of prostheses fixation to bone and gap
filler in revision arthroplasty. Growth factors are not the
only strategy available to enhance bone repair in the
future: mesenchymal stem cell research and gene therapy
have already arrived to preclinical stage.
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